Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development, process development, production of a product for preclinical and clinical trials, development and validation of analytical methods, and preparation of the necessary documentation. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.
Metrics to compare | MABP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMABPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.9x | −9.1x | −0.6x | |
PEG Ratio | 0.00 | 0.02 | 0.00 | |
Price/Book | 1.6x | 2.6x | 2.6x | |
Price / LTM Sales | 7.6x | 9.1x | 3.2x | |
Upside (Analyst Target) | 42.9% | 61.2% | 42.3% | |
Fair Value Upside | Unlock | 0.4% | 5.9% | Unlock |